Market capitalization | $145.36m |
Enterprise Value | $286.76m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 775.03 |
P/S ratio (TTM) P/S ratio | 392.86 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -99.71% |
Revenue (TTM) Revenue | $370.00k |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
6 Analysts have issued a Seres Therapeutics Inc forecast:
6 Analysts have issued a Seres Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 0.37 0.37 |
100%
100%
|
|
Gross Profit | -11 -11 |
109%
109%
|
|
EBITDA | -152 -152 |
19%
19%
|
EBIT (Operating Income) EBIT | -163 -163 |
16%
16%
|
Net Profit | -162 -162 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Eric Shaff |
Employees | 233 |
Founded | 2010 |
Website | www.serestherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.